Annual General Meeting (AGM) Statement and Q1 Trading Update

April 30, 2019

At the Company’s AGM being held today at 2.30 pm the Chairman, Christopher Pearce, will make the following statement:

“As indicated in our recent results, we remain optimistic about the future, with the near-term availability of higher-plex TMT® set to add significant value to this asset, and the utility of quantitative proteomics increasing in response to diagnostic advances and disruptive technologies.  We are pleased to report a good first quarter, with further growth in sales and royalties from TMT® and an improving services business continuing the trend in orders and revenues established during the latter part of 2018.”  

Back to News